Table 2.
Multivariable-Adjusted All-Cause Mortality Rates, and Hazard Ratios for 5ARI Users Compared to Alpha-Blocker Users Overall and Stratified by Duration of Cumulative Exposure and Cumulative Dose in the Matched Sample (N = 174,895).
| Mortality rate/ 1000 p-y |
Crude Hazard Ratio (95% CI) | Age-Adjusted Hazard Ratio (95% CI) | Multivariable Hazard ratio1 (95% CI) | ||
|---|---|---|---|---|---|
| Multivariable Adjusted | 5ARI | AB | |||
| Overall (n = 174,895, 35,266 deaths) | 118.34 | 176.65 | 0.65 (0.63,0.67)** | 0.63 (0.61,0.65)** | 0.64 (0.62,0.66)** |
| Cumulative exposure | |||||
| 0–3 months (n = 21,173, 3996 deaths) | 551.16 | 252.81 | 1.31(1.02,1.67)** | 1.15 (0.90,1.47) | 1.01 (0.79,1.29) |
| 3 months-1 year (n = 59,865, 12,951 deaths) | 130.37 | 113.27 | 0.88 (0.84,0.92)** | 0.83 (0.79,0.87)** | 0.83 (0.79,0.87)** |
| 1 year-2 years (n = 45,498, 9593 deaths) | 47.89 | 57.03 | 0.72(0.67,0.76)** | 0.70 (0.66,0.75)** | 0.75(0.70,0.80)** |
| 2+ years (n = 48,359, 8726 deaths) | 17.64 | 23.87 | 0.54 (0.52,0.57)** | 0.54 (0.51,0.57)** | 0.54 (0.51,0.57)** |
| Cumulative dose (gram) | |||||
| 1st quartile (n = 43,705, 8913 deaths) | 244.30 | 267.29 | 0.74 (0.58,0.94)** | 0.89 (0.70,1.13) | 0.97 (0.76,1.24) |
| 2nd quartile (n = 42,735, 9852 deaths) | 151.17 | 98.57 | 0.85 (0.81,0.90)** | 0.87 (0.82,0.92)** | 0.88 (0.83,0.93)** |
| 3rd quartile (n = 44,702, 9025 deaths) | 83.41 | 69.25 | 0.98 (0.92,1.03) | 0.97 (0.92,1.03) | 1.01 (0.95,1.07) |
| 4th quartile (n = 43,753, 7476 deaths) | 18.84 | 30.94 | 0.58 (0.55,0.61)** | 0.54 (0.51,0.57)** | 0.55 (0.52,0.58)** |
Results are from negative binomial regression, with the exception of the hazard ratios which were estimated using proportional hazard regression.
*
P< .05
1
Adjusted for age, BPH/LUTS initiation year, race, region, prior AB history, Charlson score, and comorbidities.